Lipidor AB re-publishes year-end report for 2019
Yesterday, 24 February at 4.59pm (CET), Lipidor AB (publ) published our year-end report for 2019 one day earlier than announced. We hereby re-publish the year-end report 2019 on the date and time earlier communicated.Summary of year-end report - fourth quarter and reporting period 2019 During the fourth quarter, the company's clinical phase III study of the drug candidate AKP01 against psoriasis was completed. The study included 277 randomized patients and was carried out by Cadila Pharmaceuticals in India. After the reporting period, positive results from the study were announced. The